Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00144
|
|||||
| Drug Name |
Daclatasvir
|
|||||
| Synonyms |
1009119-64-5; 1214735-16-6; C40H50N8O6; CHEBI:82977; CHEMBL2023898; Daclatasvir (BMS-790052); Daclatasvir (USAN); Daclatasvir BMS 790052; EX-A410; KS-00000XPC; MLS006011140; SCHEMBL17897804; SCHEMBL2756027; cc-39; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hepatitis C virus infection [ICD11: 1E50.2, 1E51.1] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C40H50N8O6
|
|||||
| Canonical SMILES |
CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC
|
|||||
| InChI |
InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1
|
|||||
| InChIKey |
FKRSSPOQAMALKA-CUPIEXAXSA-N
|
|||||
| CAS Number |
CAS 1009119-64-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 738.9 | Topological Polar Surface Area | 175 | ||
| Heavy Atom Count | 54 | Rotatable Bond Count | 13 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
5.1
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:82977
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Daclatasvir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Influence of ABCB11 and HNF4 genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. J Antimicrob Chemother. 2017 Oct 1;72(10):2846-2849. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.